The clinical application of non-genetic biomarkers for differential diagnosis monogenic diabetes

Diabetes Research and Clinical Practice

Volumn 86, Issue SUPLL.1, 2009, Pages

  Owen, Katharine R ^a,b   Skupien, Jan ^c   Malecki, Maciej T ^d,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Biomarker; Differential diagnosis; HNF1A; MODY; Monogenic diabetes

Indexed keywords

1,5 ANHYDROSORBITOL; ABC TRANSPORTER; ABC TRANSPORTER C8; APOLIPOPROTEIN M; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C8; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PREALBUMIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

AMINOACIDURIA; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; GENETIC SCREENING; GLUCOSURIA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TUBULE DISORDER; MATURITY ONSET DIABETES MELLITUS; MONOGENIC DIABETES MELLITUS; MUTATIONAL ANALYSIS; NEWBORN DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL VALUE; PATIENT SELECTION; PHARMACOGENETICS; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 72049095586     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(09)70004-X     Document Type: Article

References (37)

1. Hattersley A.T. Molecular genetics goes to the diabetes clinic. Clin Med 5 5 (2005) 476-481
2. Malecki M., Mlynarski W., and Skupien J. Can geneticists help clinicians to understand and treat non-autoimmune diabetes?. Diabetes Res Clin Pract 82 Suppl 2 (2008) S83-S93
3. Murphy R., Ellard S., and Hattersley A.T. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4 4 (2008) 200-213
4. McCarthy M.I. Susceptibility gene discovery for common metabolic and endocrine traits. J Mol Endocrinol 28 1 (2002) 1-17
5. Pearson E.R., Starkey B.J., Powell R.J., Gribble F.M., Clark P.M., and Hattersley A.T. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362 9392 (2003) 1275-1281
6. Pearson E.R., Flechtner I., Njolstad P.R., Malecki M.T., Flanagan S.E., Larkin B., et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355 5 (2006) 467-477
7. Rafiq M., Flanagan S.E., Patch A.M., Shields B.M., Ellard S., and Hattersley A.T. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 31 2 (2008) 204-209
8. Gill-Carey O.J., Shields B., Colclough K., Ellard S., and Hattersley A.T. Finding a glucokinase mutation alters treatment. Diabet Med 24 Suppl 1 (2007) A6-A20
9. Ellard S., Bellanne-Chantelot C., and Hattersley A.T. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51 4 (2008) 546-553
10. Stride A., Vaxillaire M., Tuomi T., Barbetti F., Njolstad P.R., Hansen T., et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 45 3 (2002) 427-435
11. Shepherd M., Pearson E.R., Houghton J., Salt G., Ellard S., and Hattersley A.T. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 26 11 (2003) 3191-3192
12. Schnyder S., Mullis P.E., Ellard S., Hattersley A.T., and Fluck C.E. Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment. Swiss Med Wkly 135 23-24 (2005) 352-356
13. Shepherd M., Sparkes A.C., and Hattersley A.T. Genetic testing in maturity onset diabetes of the young (MODY); a new challenge for the diabetic clinic. Practical Diabetes 18 (2001) 16-21
14. Oosterhuis W.P., Bruns D.E., Watine J., Sandberg S., and Horvath A.R. Evidence-based guidelines in laboratory medicine: principles and methods. Clin Chem 50 5 (2004) 806-818
15. Price C.P. Evidence-based laboratory medicine: supporting decision-making. Clin Chem 46 8 Pt 1 (2000) 1041-1050
16. Hawkins R.C. The evidence based medicine approach to diagnostic testing: practicalities and limitations. Clin Biochem Rev 26 2 (2005) 7-18
17. Zweig M.H., and Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39 4 (1993) 561-577
18. Hattersley A., Bruining J., Shield J., Njolstad P., and Donaghue K. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 7 6 (2006) 352-360
19. Owen K.R., Shepherd M., Stride A., Ellard S., and Hattersley A.T. Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics. Diabet Med 19 9 (2002) 758-761
20. Richter S., Shih D.Q., Pearson E.R., Wolfrum C., Fajans S.S., Hattersley A.T., et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 52 12 (2003) 2989-2995
21. Skupien J., Kepka G., Gorczynska-Kosiorz S., Gebska A., Klupa T., Wanic K., et al. Evaluation of Apolipoprotein M Serum Concentration as a Biomarker of HNF-1alpha MODY. Rev Diabet Stud 4 4 (2007) 231-235
22. Karlsson E., Shaat N., and Groop L. Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?. Diabet Med 25 7 (2008) 788-791
23. Pontoglio M., Barra J., Hadchouel M., Doyen A., Kress C., Poggi Bach J., et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal fanconi syndrome. Cell 84 (1996) 575-585
24. Stride A., Pearson E.R., Brown A., Gooding K., Castleden H.A., and Hattersley A.T. Serum amino acids in patients with mutations in the hepatocyte nuclear factor-1 alpha gene. Diabet Med 21 8 (2004) 928-930
25. Bingham C., Ellard S., Nicholls A.J., Pennock C.A., Allen J., James A.J., et al. The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1alpha mutations is a feature of all patients with diabetes and is associated with glucosuria. Diabetes 50 9 (2001) 2047-2052
26. Stride A., Ayres S., Allen L.I., Ellard S., and Hattersley A. Glycosuria at 2 h post OGTT: A screening tool for unaffected subjects in families with HNF-1a mutations. Diabet Med 19 S2 (2002) 59-60
27. Skupien J., Gorczynska-Kosiorz S., Klupa T., Wanic K., Button E.A., Sieradzki J., et al. Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. Diabetes Care 31 8 (2008) 1496-1501
28. Lee Y.-H., Sauer B., and Gonzalez F.J. Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1a knockout mouse. Mol Cell Biol 18 5 (1998) 3059-3068
29. Shih D.Q., Screenan S., Munoz K.N., Philipson L., Pontoglio M., Yaniv M., et al. Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes 50 11 (2001) 2472-2480
30. Wang H., Maechler P., Hagenfeldt K.A., and Wollheim C.B. Dominant-negative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. EMBO J 17 22 (1998) 6701-6713
31. Lockwood C.R., Bingham C., and Frayling T.M. In silico searching of human and mouse genome data identifies known and unknown HNF1 binding sites upstream of beta-cell genes. Mol Genet Metab 78 2 (2003) 145-151
32. Lockwood C.R., and Frayling T.M. Combining genome and mouse knockout expression data to highlight binding sites for the transcription factor HNF1alpha. In Silico Biol 3 1 (2002)
33. Shih D.Q., Bussen M., Sehayek E., Ananthanarayanan M., Shneider B.L., Suchy F.J., et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 27 4 (2001) 375-382
34. Faber J., Malmodin D., Toft H., Maher A., D C., Holmes E., et al. Metabonomics in Diabetes Research. J Diabetes Sci Technol 1 (2007) 549-557
35. Brindle J.T., Antti H., Holmes E., Tranter G., Nicholson J.K., Bethell H.W., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8 12 (2002) 1439-1444
36. Kirschenlohr H.L., Griffin J.L., Clarke S.C., Rhydwen R., Grace A.A., Schofield P.M., et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 12 6 (2006) 705-710
37. Yu M., Wang J., Li W., Yuan Y.Z., Li C.Y., Qian X.H., et al. Proteomic screen defines the hepatocyte nuclear factor 1alpha-binding partners and identifies HMGB1 as a new cofactor of HNF1alpha. Nucleic Acids Res 36 4 (2008) 1209-1219